On October 23, 2026, a new publication appeared in Annals of Oncology, the official journal of the European Society for Medical Oncology. The publication is titled "Overall survival with adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with high-risk HR+/HER2- early breast cancer: Six-year follow-up of the NATALEE trial." This entry reports six-year follow-up findings from the NATALEE trial. Goserelin is associated with this trial context as part of the broader treatment regimens studied in HR+/HER2- early breast cancer. The publication is indexed under PubMed ID 42918423. No specific efficacy or survival outcomes are detailed beyond the fact that six-year follow-up data have now been published. This brief reports only the existence and bibliographic details of this publication as provided. Readers seeking clinical interpretation should consult the full article in Annals of Oncology directly. For more background on goserelin, including its approved regulatory status and general context, see the compound overview.
Goserelin-Linked NATALEE Trial Six-Year Survival Data Published
See the full goserelin overview
Source: https://pubmed.ncbi.nlm.nih.gov/42918423/